This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. 2026 is an “execution year” for Teladoc Health, CEO Chuck Divita told Healthcare Dive. The telehealth company has spent the past year focusing on a strategy shift, prioritizing international expansion, improving operating efficiency, better leveraging its mental health assets and enhancing its integrated care business. The goal is to deliver sustainable lon ...

Key Points Medicare will no longer cover telemedicine services for many patients. This change will affect Teladoc Health, which was already struggling. Doximity might be less affected, but its prospects look dim as well. 10 stocks we like better than Teladoc Health › Telehealth services are convenient. There is nothing quite like being able to get some medical care, albeit virtual, from the comfort of one's home. Telehealth likely saves physicians and patients time and money. However, none of t ...

Group 1: Sarepta Therapeutics - Sarepta Therapeutics' shares declined by over 80% last year due to safety concerns surrounding its key product, Elevidys, which targets Duchenne muscular dystrophy (DMD) [3][4] - The company had to include a boxed warning for potential liver injury and restrict access to Elevidys after two patients died from liver failure [4][6] - For 2025, Sarepta expects revenue of $1.86 billion, a decline from $1.9 billion in the previous year, indicating a drop in demand for its medicine [6] - Despite efforts to develop new medicines and potential clinical progress, these products are not expected to impact financial performance in the near term [6][7] - Concerns remain regarding the safety of Sarepta's pipeline products, which could further affect investor confidence [7] Group 2: Teladoc Health - Teladoc Health has faced slow to non-existent revenue growth and accumulated net losses in recent years [8] - Increased competition in the telemedicine space has undermined Teladoc's market share, particularly affecting its virtual therapy platform, BetterHelp, which has seen a decline in paying members [9][10] - The company is attempting to improve its situation by seeking broader insurance coverage for BetterHelp and expanding internationally, but challenges similar to those faced domestically are anticipated abroad [12][13] - Teladoc's market cap stands at $1.1 billion, with a current price of $6.16, reflecting ongoing struggles in the market [11][12]

Transforming how better health happens J.P. Morgan Healthcare Conference January 2026 Safe Harbor This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of ...

Core Viewpoint - Teladoc Health has experienced a significant decline in stock value, currently trading about 98% lower than its peak in February 2021, raising questions about whether the shares are undervalued enough to consider a buy [1][2]. Financial Performance - In Q3 2025, Teladoc's revenue decreased by 2% year over year to approximately $626 million, with integrated care revenue rising by 2% to about $390 million, while BetterHelp revenue fell by 8% to around $237 million [4]. - The company reported a net loss of $49.5 million in Q3, which included a $12.6 million non-cash goodwill impairment charge, indicating ongoing struggles despite generating $67.9 million in free cash flow [11][12]. Membership and Growth Metrics - Teladoc's U.S. integrated care membership reached 102.5 million, reflecting a 9% year-over-year increase, while chronic care program enrollment was 1.17 million, showing a slight decline of 1% year over year but a sequential increase of over 4% [5]. - Key metrics for BetterHelp, such as conversion rates and user growth, are reportedly trending as expected, although the direct-to-consumer cash-pay business faces challenges due to competition [7][8]. Future Outlook - The company anticipates Q4 2025 revenue to be between $622 million and $652 million, which is lower than the previous year's Q4 revenue of approximately $640 million [13]. - Management has indicated that 2025 will be a "repositioning year" focused on product changes and improving the value proposition, particularly for BetterHelp [2][6].

Group 1 - Teladoc Health has been struggling with declining revenue as demand for its services has decreased post-pandemic, and its virtual therapy service, BetterHelp, faces stiff competition [1] - Management efforts to turn around Teladoc have not been successful, leading to a recommendation for investors to consider other healthcare stocks, particularly Pfizer [2] - Pfizer experienced significant revenue and earnings growth during the pandemic due to its leading coronavirus vaccine, Comirnaty, and antiviral treatment, Paxlovid, but has seen a decline in revenues over the past three years [4] Group 2 - Despite a 50% decline in share price over the past three years, Pfizer has a clearer path to recovery compared to Teladoc, supported by its established profit generation and strategic acquisitions [5] - Pfizer is expected to secure approvals for several new products in the coming years, targeting markets such as weight management and oncology, which are crucial for future sales and earnings growth [6] - The company has over 100 programs in clinical trials and has taken steps to mitigate potential threats, including a deal to sell some medicines at lower prices in exchange for tariff exemptions [7]

Core Viewpoint - The company is preparing to provide guidance for 2026 during the upcoming fourth quarter earnings call in February, indicating a cautious approach to growth projections due to macroeconomic uncertainties in the healthcare sector [1] Segment Summaries Integrated Care - The company anticipates potential low single-digit growth for 2026, reflecting a conservative outlook influenced by various factors including the selling season and broader economic conditions [1] BetterHelp - Further details regarding BetterHelp's performance and growth will be discussed later, suggesting that it is a significant area of focus for the company [1]

Core Insights - Teladoc Health, Inc. (TDOC) shares have decreased by 8.9% following the release of its third-quarter 2025 results, primarily due to a decline in access fee revenues, U.S. revenues, and weaker performance in the BetterHelp segment, although this was partially mitigated by strong international revenue growth and reduced expenses [1] Financial Performance - The adjusted loss per share for Q3 2025 was 21 cents, which was narrower than the Zacks Consensus Estimate of a 26-cent loss but wider than the 19-cent loss from the previous year [2] - Operating revenues fell by 2% year over year to $626.4 million, although this figure exceeded the consensus estimate by 0.2% [2] - Access fee revenues decreased by 6% year over year to $520.9 million, missing the Zacks Consensus Estimate of $534 million [3] - Other revenues increased by 24% year over year to $105.5 million, surpassing the consensus estimate of $91 million [3] Geographical Revenue Breakdown - U.S. revenues totaled $509.8 million, down 5% year over year, falling short of the Zacks Consensus Estimate of $521 million [4] - International revenues rose by 12% year over year to $116.7 million, exceeding the consensus estimate of $105 million [4] Expense Management - Total costs and expenses decreased by 1% year over year to $678.4 million, which was lower than the estimate of $691.4 million, driven by reductions in advertising, marketing, technology, and administrative expenses [5] Segment Performance - The Integrated Care segment's revenues grew by 2% year over year to $389.5 million, beating the consensus estimate [6] - The BetterHelp segment's revenues fell by 8% year over year to $236.9 million, missing the consensus estimate [7] Membership and Visits - Total visits to Teladoc Health reached 4.1 million, a 1% increase year over year, surpassing the consensus estimate of 4 million [8] - U.S. Integrated Care Members increased by 9% year over year to 102.5 million, exceeding the consensus estimate [8] Cash Flow and Financial Position - Cash and cash equivalents at the end of Q3 2025 were $726.2 million, down 44.1% from the end of 2024 [10] - Net cash from operations was $99.3 million, a decrease of 9.9% year over year [11] - Free cash flow dropped by 14% year over year to $67.9 million [11] Future Outlook - For Q4 2025, Integrated Care segment revenues are expected to grow by 1-5.2% year over year, while BetterHelp segment revenues are projected to decline by 8.8-3.8% [12] - Total revenues for Q4 are anticipated to be between $622 million and $652 million [13] - For the full year 2025, total revenues are now expected to be between $2.510 billion and $2.539 billion, with an adjusted EBITDA forecast of $270-$287 million [16]

Core Insights - Teladoc reported revenue of $626.44 million for the quarter ended September 2025, a decrease of 2.2% year-over-year, with an EPS of -$0.21 compared to -$0.19 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $625.02 million by 0.23%, while the EPS surprised positively by 19.23% against the consensus estimate of -$0.26 [1] Financial Performance Metrics - Average Monthly Revenue Per U.S. Integrated Care Member was $1.27, matching analyst estimates [4] - BetterHelp Paying Users totaled 0.38 million, slightly below the estimated 0.39 million [4] - U.S. Integrated Care Members reached 102.5 million, exceeding the average estimate of 102.26 million [4] - Chronic Care Program Enrollment was 1.17 million, slightly above the estimate of 1.16 million [4] Revenue by Segment - Integrated Care revenue was $389.54 million, surpassing the estimate of $388.13 million, reflecting a year-over-year increase of 1.5% [4] - BetterHelp revenue was $236.9 million, below the estimate of $237.7 million, indicating a year-over-year decline of 7.8% [4] - BetterHelp-Other Wellness Services generated $5.1 million, compared to the estimate of $5.28 million, representing an 18.5% year-over-year decrease [4] - BetterHelp-Therapy Services revenue was $231.8 million, slightly below the estimate of $231.99 million, showing a 7.5% decline year-over-year [4] Revenue by Type - Other revenue amounted to $105.53 million, exceeding the estimate of $90.63 million, with a year-over-year increase of 23.8% [4] - Access fees revenue was $520.91 million, below the estimate of $533.92 million, reflecting a 6.2% year-over-year decline [4] Adjusted EBITDA - Adjusted EBITDA for BetterHelp was $3.84 million, significantly lower than the average estimate of $8.46 million [4] - Adjusted EBITDA for Integrated Care was $66.07 million, exceeding the estimate of $59.01 million [4] Stock Performance - Teladoc shares returned +8.2% over the past month, outperforming the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Teladoc reported third-quarter revenue of $626.4 million and consolidated adjusted EBITDA of $69.9 million, reaffirming its full-year revenue and adjusted earnings outlook for 2025, expecting revenue between $2.5 billion and $2.55 billion, with adjusted EBITDA ranging from $263 million to $294 million [3][8] Leadership Changes - CFO Mala Murthy will step down effective November 21, 2023, to pursue an opportunity outside the healthcare sector, marking a significant leadership change as the company is undergoing a strategic revamp under CEO Chuck Divita [5][8] - Teladoc is in the process of identifying a new CFO and establishing an interim leadership structure with key finance leaders reporting directly to the CEO [5][8] Strategic Focus - The company is prioritizing enhancements in its business-to-business integrated care unit, international expansion, and better leveraging its position in mental healthcare [6] - Teladoc's direct-to-consumer mental health service, BetterHelp, has faced challenges with declining revenue and fewer paying customers, prompting the company to add new payment options and accept insurance to increase affordability and consumer enrollment [6][7] Market Context - Analysts note that while the departure of a CFO is typically viewed negatively, the pre-release of third-quarter results that met investor expectations may help alleviate concerns [4][8] - The company is navigating a transitional phase characterized by slower growth and a challenging end-market environment [4]